Dentium (145720) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Dentium stock KRW 42,294, price KRW 38,950, upside +8.6%, quality 36 out of 100. Rating: fairly valued. Calculated from audited financials with 16 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.
How to read this chart
60‑month range 36,350 KRW – 172,044 KRW · fair‑value band 41,664 KRW – 45,131 KRW · the 38,950 KRW price screens below the 42,294 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 7, 2026.
Follow Dentium in your weekly email
Every Wednesday you see whether Dentium is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Dentium CO., LTD manufactures and sells dental medical instrument worldwide. Its implant systems include superline, implantium, implantium 2, N.R. line, simple line 2, and slim line. The company also provides block and coloring; regeneration products; and digital dentistry products.
Show moreShow less
In addition, it offers orthodontics, bright resin, tooth care, and other dental products. The company was formerly known as Biostech Co., Ltd. and changed its name to Dentium Co.,Ltd. in August 2002. Dentium Co.,Ltd. was founded in 2000 and is headquartered in Seoul, South Korea.
Stock analysis
Dentium (145720) currently trades at 38,950 KRW, while our model-based Fair Value estimate is 42,294 KRW, so the stock looks roughly fairly valued today (gap 7.9%).
Show more
Valuation
Bull case: the Multiples group reads highest at a median of 91,411 KRW per share, and 9 of the 16 models we run sit above the 38,950 KRW price.
Bear case: the Dividend Discount group reads lowest at 7,687 KRW, and 7 of the 16 models stay below the price. Data coverage for this calculation is high.
Scenario range: 41,664 KRW (bear) to 45,131 KRW (bull), the price of 38,950 KRW sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 36/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Dentium reported revenue of 346B KRW in FY2025 versus 292B KRW in FY2021, a compound +4.4%/yr. Reported net income was 16.4B KRW in FY2025, compounding −26.3%/yr from FY2021.
Key figures
Market cap 336B KRW (≈ $248M) Micro · P/E ratio 10.4 · P/S ratio 0.97 · EPS (TTM) 3,645 KRW · Dividend yield 1.5% · Net margin 8.7% · Return on equity 5.2% · Return on assets (EBIT) 13.3% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).
What moves the price
The share trades about 32% below its 52-week high and 7% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −44% fair-value upside, at 9%, 145720 screens cheaper than that median.
Fair Value models
Bear41,664 KRWFair Value 42,294 KRWBull45,131 KRW
Price 38,950 KRW · Upside +8.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (2,611 KRW per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.30/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−15.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.6%
Start year 2020 (pandemic). Over 10 years: +13.8% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.8%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−4.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year−6.2%
Dividend (yield on the price)1.5%
Profit margin 2019 to 2024 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.18% → 24%
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 181 stocks
Beats the industry median on 8/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score36 · Bottom 25%
Fair Value upside+8.6% · Above median
Profitability
Return on equity (12 months)5.2% · Below median
Return on assets1.8% · Below median
Net margin (12 months)8.7% · Above median
Operating margin (12 months)16.4% · Above median
Growth and dividend
Revenue growth (quarter YoY)8.6% · Above median
Dividend yield (12 months)1.5% · Below median
Balance sheet
Debt / equity0.08× · Above median
Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Dentium Fair Value". https://www.fairvalue-calculator.com/stock/145720
Frequently asked questions
Is Dentium (145720) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of 42,294 KRW versus a price of 38,950 KRW, about +9% upside (fairly valued).
What is the fair value of 145720?
Our model-based fair value for Dentium is 42,294 KRW (as of Nov 7, 2026), built from audited fundamentals. The current price: 38,950 KRW.
What is the quality score of 145720?
Dentium has a Quality Score of 36/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Dentium (145720)?
Our model-based price target is the fair value of 42,294 KRW (as of Nov 7, 2026) from 16 valuation models. Cautious scenario 41,664 KRW, optimistic scenario 45,131 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Dentium stock forecast for 2026?
Our models put fair value at 42,294 KRW, about +9% upside versus a price of 38,950 KRW (fairly valued). Cautious scenario 41,664 KRW, optimistic scenario 45,131 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Dentium (145720)?
Dentium reported trailing-twelve-month revenue of about 348B KRW (latest available figure, as of Nov 7, 2026).
Does Dentium pay a dividend?
Dentium currently shows a dividend yield of 1.54% relative to its recent price (as of Nov 7, 2026).
How much is the dividend of Dentium (145720) and when is the ex-dividend date?
Dentium pays a dividend of 600.00 KRW per share a year, a dividend yield of 1.5%. The last ex-dividend date was Mar 20, 2026. The payout ratio is 16.5% of earnings. Our assessment: Watch coverage. The dividend isn’t fully covered by free cash flow or earnings, part of it is funded from reserves or debt. Fine for now, but worth watching: if it stays uncovered, the dividend could be cut.
What is the intrinsic value of Dentium (145720)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Dentium it is 42,294 KRW per share (as of Nov 7, 2026), against a price of 38,950 KRW. It is the blended result of 16 valuation models in 6 families (Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Dentium stock overvalued or undervalued in 2026?
As of Nov 7, 2026, 145720 trades below its calculated fair value: price 38,950 KRW, fair value 42,294 KRW, a gap of about +9% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 145720?
No. The price is what the market pays today (38,950 KRW); the fair value is what the company's own numbers justify (42,294 KRW). For Dentium the two are 3,344 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Dentium worth?
The market values Dentium at about 336B KRW (market capitalisation, as of Nov 7, 2026). Per share that is 38,950 KRW; our models calculate a fair value of 42,294 KRW per share.
What do the bullish and bearish scenarios say about 145720?
Our models span a range for Dentium: cautious scenario 41,664 KRW, base 42,294 KRW, optimistic 45,131 KRW per share (as of Nov 7, 2026, price 38,950 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 145720?
Dentium trades at a price-to-earnings ratio of 10.4 (as of Nov 7, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 42,294 KRW is built from several models across several years. Median P/E at fiscal year-end, 9 fiscal years (2017 to 2025), reported earnings, FY2025 ex one-offs: 14.5. Other multiples: P/B 0.6, P/S 1.0, EV/EBITDA 3.2.
How solid is the balance sheet of Dentium (145720)?
Balance-sheet figures for Dentium (as of Nov 7, 2026): return on equity 5.2%, debt of 0.08 per unit of equity. They feed the Quality Score of 36/100, which measures business quality independently of the share price.
How far is 145720 from its 52-week high?
Dentium trades at 38,950 KRW, about 32% below its 52-week high of 57,626 KRW and 7% above the low of 36,350 KRW (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 42,294 KRW is for.
Which stocks are comparable to Dentium?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Dentium stock attractive at the current price?
The data as of Nov 7, 2026: price 38,950 KRW, calculated fair value 42,294 KRW (+9%), Quality Score 36/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 145720 calculated?
We run Dentium through 16 models from 6 families: Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 42,294 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Dentium currently trades 8% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Dentium (145720)?
The closing price on Nov 6, 2026 was 38,950 KRW. Our model-based fair value is 42,294 KRW, about +9% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Dentium right now?
The price is below even our cautious bear case (41,664 KRW). The market is more pessimistic than our downside scenario. The price sits close to our fair value, market and models broadly agree here, little valuation tension. The models converge in a tight band (41,664 KRW to 45,131 KRW), unusually little disagreement for a valuation.
Key figures of Dentium
How large is the market capitalisation of Dentium (145720)?
The market capitalisation of Dentium is 336B KRW (≈ $248M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Dentium (145720)?
The price-to-sales ratio of Dentium is 0.97 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Dentium (145720)?
Earnings per share at Dentium are 3,645 KRW (price ÷ EPS = P/E 10.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Dentium (145720)?
The dividend yield of Dentium is 1.5% (payout 16.5%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Dentium (145720)?
The net margin of Dentium is 8.7% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Dentium (145720)?
The return on equity (ROE) of Dentium is 5.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Dentium (145720)?
On an EBIT basis the return on assets of Dentium is 13.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Dentium (145720)?
The operating margin of Dentium is 16.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Dentium (145720)?
Revenue at Dentium is growing +8.6% versus a year earlier (3y avg −0.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Dentium (145720)?
Earnings per share at Dentium are growing +197% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Dentium (145720) generate?
The free cash flow of Dentium is −40.3B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Dentium (145720) carry?
The net debt of Dentium is 206B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Dentium in the live analysis
One click puts Dentium on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 7, 2026